<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2201233132
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIPIDIA 25 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALOGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        105.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC Sult" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC Sult
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vipidia contains the active substance alogliptin which belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) which are &ldquo;oral anti-diabetics&rdquo;. It is used to lower blood sugar levels in adults with type 2 diabetes. Type 2 diabetes is also called non-insulin dependent diabetes mellitus or NIDDM.<br />Vipidia works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body. It must be taken together with other anti-diabetic medicines, which your doctor will have prescribed for you, such as sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide),metformin and/or thiazolidinediones (e.g. pioglitazone) and metformin and/or insulin.<br />Vipidia is taken when your blood sugar cannot be adequately controlled by diet, exercise and one or more of these other oral anti-diabetic medicines. It is important that you continue to take your other anti-diabetic medicine, and continue to follow the advice on diet and exercise that your nurse or doctor has given you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vipidia</strong></p><ul><li>If you are allergic to alogliptin or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. Additional symptoms may include general itching and feeling of heat especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome).</li></ul><p><strong>Warnings and Precautions</strong><br />Talk to your doctor or pharmacist before taking Vipidia:</p><ul><li>If you have type 1 diabetes (your body does not produce insulin)</li><li>If you have diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to breakdown glucose because there is not enough insulin). Symptoms include excessive thirst, frequent urination, loss of appetite, nausea or vomiting and rapid weight loss</li><li>If you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, glibenclamide) or insulin. Your doctor may want to reduce your dose of sulphonylurea or insulin when you take any of them together with Vipidia in order to avoid too low blood sugar (hypoglycaemia)</li><li>If you have kidney disease, you can still take this medicine but your doctor may reduce the dose</li><li>If you have liver disease</li><li>If you suffer from heart failure</li><li>If you are taking insulin or an anti-diabetic medicine, your doctor may want to reduce your dose of the other anti-diabetic medicine or insulin when you take either of them together with Vipidia in order to avoid low blood sugar</li><li>If you have or have had a disease of the pancreas</li></ul><p><strong>Children and adolescents</strong><br />Vipidia is not recommended for children and adolescents under 18 years due to the lack of data in these patients.</p><p><strong>Other medicines and Vipidia</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />There is no experience of using Vipidia in pregnant women or during breast-feeding. Vipidia should not be used during pregnancy or breast-feeding. Your doctor will help you to decide whether to continue breast-feeding or to continue using Vipidia.</p><p><strong>Driving and using machines</strong><br />Vipidia is not known to affect your ability to drive and use machines. Taking Vipidia in combination with other anti-diabetic medicines called sulphonylureas, insulin or combination therapy with thiazolidinedione plus metformin can cause too low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />Your doctor will prescribe Vipidia together with one or more other medicines to control your blood sugar levels. Your doctor will tell you if you need to change the amount of other medicines you take.</p><p>The recommended dose of Vipidia is 25 mg once a day.</p><p><em>Patients with kidney disease</em><br />If you have kidney disease your doctor may prescribe you a reduced dose. This may be 12.5 mg or 6.25 mg once a day, depending on the severity of your kidney disease.</p><p><em>Patients with liver disease</em><br />If you have mildly or moderately reduced liver function, the recommended dose of Vipidia is 25 mg once a day. This medicine is not recommended for patients with severely reduced liver function due to the lack of data in these patients.<br />Swallow your tablet(s) whole with water. You can take this medicine with or without food.</p><p><strong>If you take more Vipidia than you should</strong><br />If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that your doctor knows exactly what you have taken.</p><p><strong>If you forget to take Vipidia</strong><br />If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Vipidia</strong><br />Do not stop taking Vipidia without consulting your doctor first. Your blood sugar levels may increase when you stop taking Vipidia.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Alogliptin can cause serious side effects, including:</p><ul><li>Joint pain. Some people who take medicines called DPP-4 inhibitors like alogliptin, may develop joint pain that can be severe. Call your doctor if you have severe joint pain.</li><li>Skin reaction. Some people who take medicines called DPP-4 inhibitors, like alogliptin, may develop a skin reaction called bullous pemphigoid that can require treatment in a hospital. Tell your doctor right away if you develop blisters or the breakdown of the outer layer of your skin (erosion). Your doctor may tell you to stop taking alogliptin.</li></ul><p>STOP taking alogliptin and contact a doctor immediately if you notice any of the following serious side effects:</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><ul><li>An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing problems, swelling of your lips, face, throat or tongue and feeling faint.</li><li>A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme).</li><li>&nbsp;Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).</li></ul><p>You should also discuss with your doctor if you experience the following side effects</p><p><strong>Common</strong> (may affect up to 1 in 10 people):</p><ul><li>&nbsp;Symptoms of low blood sugar (hypoglycaemia) may occur when alogliptin is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide).</li></ul><p><em>Symptoms may include:</em> trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change or feeling confused. Your blood sugar could fall below the normal level, but can be increased again by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.</p><ul><li>Cold like symptoms such as sore throat, stuffy or blocked nose,</li><li>&nbsp;Rash</li><li>&nbsp;Itchy skin</li><li>&nbsp;Headache</li><li>&nbsp;Stomach ache</li><li>&nbsp;Diarrhoea</li><li>&nbsp;Indigestion, heartburn</li></ul><p><strong>Not known:</strong></p><ul><li>Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 30&deg;C.<br />Store in the original package.<br />Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not use this medicine if you notice any visible signs of deterioration.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is alogliptin benzoate.</p><p>Each film-coated tablet of Vipidia 12.5 mg Film-coated Tablets contains 17 mg alogliptin benzoate equivalent to 12.5 mg alogliptin.</p><p>Each film-coated tablet of Vipidia 25 mg Film-coated Tablets contains 34 mg alogliptin benzoate equivalent to 25 mg alogliptin.</p><p>The other ingredients are:<em> Tablet core:</em> Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate. <em>Tablet coat</em>: Hypromellose, titanium dioxide, ferric oxide yellow (in Vipidia 12.5 mg only), ferric oxide red (in Vipidia 25 mg only) and polyethylene glycol. <em>Printing ink: </em>Opacode black.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vipidia 12.5 mg Film-coated Tablets are yellow oval biconvex film-coated tablets with “TAK ALG-12.5” printed on one side in aluminum/aluminum blisters.
Vipidia 25 mg Film-coated Tablets are light red oval biconvex film-coated tablets with “TAK ALG-25” printed on one side in aluminum/aluminum blisters.
Pack size: 28 film-coated tablets..
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: jpimedical@hikma.com</p><p><strong>Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC</p><p>P.O. Box 42</p><p>Sult, Jordan</p><p>Tel: + (962-5)3492200</p><p>Fax: + (962-5)3492203</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2020; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ڤيبيديا على المادة الفعالة ألوغليبتين التي تنتمي إلى مجموعة الأدوية التي تدعى مثبطات ثنائي ببتيديل ببتيداز- 4 وهي<br />خافضات سكر الدم التي تعطى عن طريق الفم. يستخدم هذا الدواء لخفض مستويات السكر في الدم عند البالغين الذين يعانون من&nbsp;السكري النوع الثاني. يدعى السكري النوع الثاني بداء السكري غير المعتمد على الإنسولين.<br />يعمل ڤيبيديا على زيادة مستويات الأنسولين في الجسم بعد الوجبة وتقليل كمية السكر في الجسم. يجب أن يتم تناوله مع الأدوية<br />الأخرى الخافضة للسكر التي سيصفها لك طبيبك مثل السلفونيليوريا (مثل غليبيزيد، تولبوتاميد، غليبانكلاميد)، ميتفورمين، و/أو ثيازوليدينديون (مثل بيوغليتازون) و ميتفورمين و/أو الأنسولين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم ڤيبيديا:</p><ul><li>إذا كنت تعاني من حساسية لألوغليبتين أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المدرجة في القسم 6).</li><li>إذا سبق وحدث لديك رد فعل تحسسي خطير لأي أدوية أخرى مشابهة والتي تتناولها للسيطرة على مستوى السكر في دمك. تتضمن أعراض رد الفعل التحسسي الخطير: طفح جلدي، بقع بارزة لونها أحمر على جلدك(شرى)، تورم في الوجه، الشفتين، اللسان والحلق والذي قد يؤدي إلى صعوبة في التنفس أوالبلع. قد تتضمن الأعراض الإضافية حكة عامة وشعور بالحرارة خاصة في فروة الرأس، الفم، الحلق، راحة اليدين وأخمص القدمين (متلازمة ستيفنز جونسون).</li></ul><p><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول ڤيبيديا:</p><ul><li dir="rtl">اذا كنت تعاني من مرض السكري النوع الأول (عندما لا يملك جسمك القدرة على تصنيع الأنسولين)</li><li dir="rtl">إذا كنت تعاني من حُماض كيتوني سكري (من المضاعفات الناتجة عن السكري والتي تحدث عندما يكون الجسم غير قادر على تكسير الغلوكوز بسبب عدم توفر ما يكفي من الأنسولين). تتضمن الأعراض العطش الشديد، التبول المتكرر، فقدان الشهية، غثيان أو قيء وفقدان سريع في الوزن.</li><li dir="rtl">إذا كنت تتناول أدوية خافضة للسكر والتي تعرف بالسلفونيليوريا (مثل غليبيزيد، تولبوتاميد، غليبانكلاميد)&nbsp;أو الأنسولين. قد يرغب طبيبك بتخفيض جرعتك من السلفونيليوريا أو من الأنسولين عند تناول أي منهما معاً مع ڤيبيديا وذلك لتجنب انخفاض مستوى السكر في الدم (نقص سكر الدم)</li><li dir="rtl">إذا كنت تعاني من مرض في الكلى، لا يزال بإمكانك تناول هذا الدواء لكن قد يعمل طبيبك على تخفيض الجرعة</li><li dir="rtl">إذا لديك مرض في الكبد</li><li dir="rtl">إذا كنت تعاني من فشل في القلب</li><li dir="rtl">إذا كنت تتناول الأنسولين أو دواء خافض للسكر، قد يرغب طبيبك بتخفيض جرعة الأدوية الأخرى الخافضة للسكر أو الأنسولين عند تناول أي منهما معاً مع ڤيبيديا وذلك لتجنب انخفاض مستوى السكر في الدم</li><li dir="rtl">إذا سبق وكنت تعاني، أو لديك مرض في البنكرياس</li></ul><p><strong>الأطفال والمراهقين</strong></p><p>لا يوصى بإعطاء ڤيبيديا للأطفال والمراهقين دون سن 18 عاماً بسبب نقص البيانات في هؤلاء المرضى.<br /><strong>الأدوية الأخرى و ڤيبيديا</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أي أدوية أخرى.<br /><strong>الحمل والرضاعة</strong><br />يرجى استشارة طبيبك أو الصيدلي للحصول على النصيحة قبل تناول هذا الدواء إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، تعتقدين بأنك قد تكونين حاملاً أو تخططين لإنجاب طفل.<br />لا تتوفر الخبرة في استخدام ڤيبيديا في النساء الحوامل أو خلال الرضاعة الطبيعية. لا يجب استخدام ڤيبيديا خلال الحمل أو الرضاعة الطبيعية. سيقوم طبيبك بمساعدتك على اتخاذ القرار بشأن مواصلة الرضاعة الطبيعية أو الاستمرار في تناول ڤيبيديا.<br /><strong>تأثير ڤيبيديا على القيادة واستخدام الآلات</strong><br />لا يعرف ڤيبيديا بقابليته على التأثير على قدرتك على القيادة واستخدام الآلات. تناول ڤيبيديا بالتزامن مع أدوية أخرى خافضة للسكر تدعى السلفونيليوريا، الأنسولين أو العلاج المركب المؤلف من ثيازوليدينديون مع ميتفورمين قد يؤدي إلى انخفاض مستويات السكر&nbsp;في الدم (نقص سكر الدم)، والتي قد تؤثر على قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول هذا الدواء تماماً كما أخبرك طبيبك أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا لم تكن متأكداً. سيصف طبيبك ڤيبيديا مع دواء واحد أو العديد من الأدوية الأخرى للتحكم بمستويات السكر في دمك. سيخبرك طبيبك إذا كنت&nbsp;بحاجة إلى تغيير جرعة الأدوية الأخرى التي تتناولها.<br />الجرعة الموصى بها من ڤيبيديا هي 25 ملغم مرة في اليوم.</p><p>المرضى الذين يعانون من مرض في الكلى<br />قد يصف لك طبيبك جرعة مخفّضة، إذا كانت تعاني من مرض في الكلى. قد تكون 12.5 ملغم أو 6.25 ملغم مرة في اليوم، اعتماداً على شدة المرض في الكلى.<br />المرضى الذين يعانون من مرض في الكبد<br />إذا كان لديك انخفاض خفيف أو معتدل في وظيفة الكبد، تكون الجرعة الموصى بها هي 25 ملغم مرة في اليوم. لا يوصى بإعطاء هذا الدواء للمرضى الذين يعانون من انخفاض شديد في وظيفة الكبد بسبب نقص توفر البيانات في هؤلاء المرضى.<br />قم ببلع الأقراص كاملة مع الماء. يمكن تناول هذا الدواء مع الأكل أو بدونه.<br /><strong>إذا تناولت جرعة زائدة من ڤيبيديا</strong><br />إذا تناولت أكثر مما يلزم من الأقراص، أو إذا تناول شخص آخر أو طفل دواؤك، اتصل أو اذهب إلى أقرب مركز طوارىء على الفور. قم بأخذ هذه النشرة أو بعض من الأقراص معك ليتمكن طبيبك من معرفة ما قمت بتناوله بالضبط.<br /><strong>إذا نسيت تناول ڤيبيديا</strong><br />إذا نسيت تناول جرعة، قم بتناولها فور تذكرها. لا تقم بتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.<br /><strong>إذا توقفت عن تناول ڤيبيديا</strong><br />لا تتوقف عن تناول ڤيبيديا دون استشارة طبيبك أولاً. قد ترتفع مستويات السكر في دمك إذا توقفت عن تناول ڤيبيديا.<br />إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.<br />يمكن أن يسبب ألوغليبتين آثاراً جانبية خطيرة، بما في ذلك:</p><ul><li dir="rtl">ألم في المفاصل. قد يصاب بعض الأشخاص الذين يتناولون أدوية تسمى مثبطات ثنائي ببتيديل ببتيداز- 4 مثل ألوغليبتين بآلام المفاصل التي يمكن أن تكون شديدة. اتصل بطبيبك إذا كنت تعاني من آلام شديدة في المفاصل.</li><li dir="rtl">ردود فعل جلدية. قد يصاب بعض الأشخاص الذين يتناولون أدوية تسمى مثبطات ثنائي ببتيديل ببتيداز- 4، مثل ألوغليبتين، برد فعل جلدي يسمى شبيه الفقاع الفقاعي الذي يمكن أن يتطلب العلاج في المستشفى. أخبر طبيبك على الفور إذا أصبت ببثور أو&nbsp;تمزق في الطبقة الخارجية من جلدك (تآكل). قد يخبرك طبيبك بالتوقف عن تناول ألوغليبتين.</li></ul><p>توقف عن تناول ألوغليبتين، واتصل بالطبيب فوراً إذا لاحظت أي من الأعراض الجانبية التالية:</p><p><strong>غير معروفة </strong>(لا يمكن تقدير شيوعها من البيانات المتاحة):</p><ul><li>تفاعل تحسسي. قد تتضمن الأعراض: طفح جلدي، شرى، مشاكل في التنفس أو البلع، تورم في الشفتين، الوجه، الحلق أو اللسان والشعور بالإغماء.</li><li>تفاعل تحسسي شديد: آفات جلدية أو بقع على جلدك والتي قد تتطور إلى قرحة تحيطها حلقات باهتة أو حمراء اللون، تنفط و/أو تقشر الجلد مع احتمالية وجود أعراض مثل الحكة، الحمى، الشعور بالمرض بشكل عام، ألم في المفاصل، مشاكل في البصر، الشعور بحرقة، ألم أو حكة في العينين وتقرحات في الفم (متلازمة ستيفنز جونسون وحُمامى عديدة الأشكال).</li><li>ألم شديد ومستمر في البطن (منطقة المعدة) والذي قد يصل إلى الظهر، وكذلك الغثيان والقيء والذي قد يكون علامة على التهاب البنكرياس.</li></ul><p>كما يجب عليك أن تتناقش مع طبيبك إذا عانيت من أي من الأعراض الجانبية التالية:</p><p><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين 10 أشخاص)</p><ul><li>قد تحدث أعراض انخفاض مستوى السكر في الدم(نقص سكر الدم) عندما يتم تناول ألوغليبتين بالتزامن مع الأنسولين أو أدوية السلفونيليوريا&nbsp; (مثل غليبيزيد، تولبوتاميد، غليبانكلاميد).</li></ul><p>قد تتضمن الأعراض: الإرتعاش، التعرق، القلق، عدم وضوح في الرؤية، نخز الشفتين، شحوب، تقلب المزاج أو الشعور بالارتباك. قد يهبط لديك مستوى السكر دون المستوى الطبيعي، لكن يمكن رفعه مرة أخرى بتناول السكر. يوصى بأن تبقي معك مكعبات سكر، حلويات، بسكويت أو عصير فاكهة يحتوي على السكر.</p><ul><li>أعراض البرد مثل إلتهاب الحلق، أو احتقان الأنف،</li><li>طفح جلدي</li><li>حكة في الجلد</li><li>&nbsp;صداع</li><li>ألم في المعدة</li><li>&nbsp;إسهال</li><li>عسر في الهضم، حرقة</li></ul><p><strong>غير معروفة</strong><br />مشاكل في الكبد مثل الغثيان أو القيء، ألم في المعدة، تعب غير مفسر وغير طبيعي، فقدان الشهية، بول غامق أو اصفرار جلدك أو بياض عينيك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.<br />لا يحفظ عند درجة حرارة أعلى من 30 &deg; مئوية.<br />يحفظ داخل العبوة الأصلية.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك&nbsp;الشهر.<br />لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.<br />لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم&nbsp;تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي بنزوات الألوغليبتين.<br />يحتوي كل قرص مغطى بطبقة رقيقة من ڤيبيديا 12.5 ملغم أقراص مغطاة بطبقة رقيقة على 17&nbsp;ملغم بنزوات الألوغليبيتين&nbsp;تكافئ 12.5 ملغم ألوغليبيتين.<br />يحتوي كل قرص مغطى بطبقة رقيقة من ڤيبيديا 25 ملغم أقراص مغطاة بطبقة رقيقة&nbsp;على 34 ملغم بنزوات الألوغليبيتين تكافئ 25 ملغم ألوغليبيتين.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص:</em> مانيتول، سيلليلوز بلوري مكروي، هيدروكسي بروبيل<br />السيلليلوز، كروسكارميللوز الصوديوم وستيرات المغنيسيوم.<em> غلاف القرص</em>: هيبروميللوز، ثنائي أكسيد التيتانيوم، أكسيد الحديد<br />الأصفر ( في ڤيبيديا 12.5 ملغم فقط)، أكسيد الحديد الأحمر ( في ڤيبيديا 25 ملغم فقط)&nbsp;وغليكول متعدد الإيثيلين&nbsp;حبر الطباعة: أوباكود أسود.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ڤيبيديا 12.5 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص ذات لون أصفر، بيضاوية الشكل، محدبة الوجهين، مطبوع عليها &rdquo;TAK ALG-12.5&ldquo; على جهة واحدة معبأة في أشرطة من الألمينيوم/الألمينيوم.<br />ڤيبيديا 25 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص ذات لون أحمر فاتح، بيضاوية الشكل، محدبة الوجهين، مطبوع عليها &rdquo;TAK ALG-25&ldquo; على جهة واحدة معبأ في أشرطة من الألمينيوم/الألمينيوم.<br />حجم العبوة: 28 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666 ، المملكة العربية السعودية<br />هاتف: 8107023 (11 - 966) +، 2142472 (11 - 966)+<br />فاكس: 2078170 (11 - 966) +<br />البريد الإلكتروني:jpimedical@hikma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             2020/10 رقم النسخة .SA3.0
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vipidia 25 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 34 mg alogliptin benzoate equivalent to 25 mg alogliptin. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Light red oval biconvex film-coated tablets, with “TAK ALG-25” printed on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>For the different dose regimens, Vipidia is available in strengths of 25 mg, 12.5 mg and 6.25 mg film-coated tablets.</p><p><strong>Adults (&ge; 18 years old)</strong></p><p>The recommended dose of alogliptin is one tablet of 25 mg once daily as add-on therapy to metformin, a thiazolidinedione, a sulphonylurea, or insulin or as triple therapy with metformin and a thiazolidinedione or insulin.</p><p>When alogliptin is used in combination with metformin and/or a thiazolidinedione, the dose of metformin and/or the thiazolidinedione should be maintained, and Vipidia administered concomitantly.</p><p>When alogliptin is used in combination with a sulphonylurea or insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4).</p><p>Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4). In case of hypoglycaemia, a lower dose of the thiazolidinedione or metformin may be considered.</p><p><strong>Special populations</strong></p><p><em>Elderly (&ge; 65 years old)</em></p><p>No dose adjustment is necessary based on age. However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population.</p><p><em>Renal impairment</em></p><p>For patients with mild renal impairment (creatinine clearance (CrCl) &gt; 50 to &le; 80 mL/min), no dose adjustment of alogliptin is necessary (see section 5.2).</p><p>For patients with moderate renal impairment (CrCl e &ge; 30 to &le; 50 mL/min), one-half of the recommended dose of alogliptin should be administered (12.5 mg once daily; see section 5.2).</p><p>For patients with severe renal impairment (CrCl &lt; 30 mL/min) or end-stage renal disease requiring dialysis, one-quarter of the recommended dose of alogliptin should be administered (6.25 mg once daily). Alogliptin may be administered without regard to the timing of dialysis. Experience in patients requiring renal dialysis is limited. Alogliptin has not been studied in patients undergoing peritoneal dialysis (see sections 4.4 and 5.2).</p><p>Appropriate assessment of renal function is recommended prior to initiation of treatment and periodically thereafter (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child- Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.4 and 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Vipidia in children and adolescents &lt; 18 years old have not been established. No data are available.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Vipidia should be taken once daily with or without food. The tablets should be swallowed wholewith water.</p><p>If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Vipidia should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Vipidia is not a substitute for insulin in insulin-requiring patients.</p><p><u>Use with other antihyperglycaemic medicinal products and hypoglycaemia</u></p><p>Due to the increased risk of hypoglycaemia in combination with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin, a lower dose of these medicinal products may be considered to reduce the risk of hypoglycaemia when these medicinal products are used in combination with alogliptin (see section 4.2).</p><p><u>Combinations not studied</u></p><p>Alogliptin has not been studied in combination with sodium glucose cotransporter 2 (SGLT-2) inhibitors or glucagon like peptide 1 (GLP-1) analogues nor formally as triple therapy with metformin and a sulphonylurea.</p><p><u>Renal impairment</u></p><p>As there is a need for dose adjustment in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of alogliptin therapy and periodically thereafter (see section 4.2).</p><p>Experience in patients requiring renal dialysis is limited. Alogliptin has not been studied in patients undergoing peritoneal dialysis (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment</u></p><p>Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.2 and 5.2).</p><p><u>Cardiac failure</u></p><p>Experience of alogliptin use in clinical studies in patients with congestive heart failure of New York Heart Association (NYHA) functional class III and IV is limited and caution is warranted in these patients.</p><p><u>Hypersensitivity reactions</u></p><p>Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.</p><p><u>Acute pancreatitis</u></p><p>Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per 1,000 patient years, respectively. In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, Vipidia should be discontinued; if acute pancreatitis is confirmed, Vipidia should not be restarted. Caution should be exercised in patients with a history of pancreatitis.</p><p><u>Hepatic effects</u></p><p>Post-marketing reports of hepatic dysfunction including hepatic failure have been received. A causal relationship has not been established. Patients should be observed closely for possible liver abnormalities. Obtain liver function tests promptly in patients with symptoms suggestive of liver injury. If an abnormality is found and an alternative etiology is not established, consider discontinuation of alogliptin treatment.</p><p><u>Severe and disabling arthralgia</u></p><p>There have been post-marketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.</p><p><u>Bullous pemphigoid</u></p><p>Post-marketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving alogliptin. If bullous pemphigoid is suspected, alogliptin should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.</p><p><u>Macrovascular outcomes</u></p><p>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with alogliptin or any other antidiabetic drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on alogliptin</u></p><p>Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). Interactions with CYP inhibitors are thus not expected and have not been shown.</p><p>Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin</p><p><u>Effects of alogliptin on other medicinal products</u></p><p><em>In vitro </em>studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. In studies <em>in vitro</em>, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.</p><p>In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing <em>in vivo </em>evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.</p><p>In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin.</p><p><u>Combination with other anti-diabetic medicinal products</u></p><p>Results from studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha- glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy Category: B.</p><p>There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.</p><p><u>Breast-feeding</u></p><p>It is unknown whether alogliptin is excreted in human milk. Animal studies have shown excretion of alogliptin in milk (see section 5.3). A risk to the suckling child cannot be excluded.</p><p>A decision on whether to discontinue breast-feeding or to discontinue alogliptin therapy should be made taking into account the benefit of breast-feeding for the child and the benefit of alogliptin therapy for the woman.</p><p><u>Fertility</u></p><p>The effect of alogliptin on fertility in humans has not been studied. No adverse effects on fertility were observed in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vipidia has no or negligible influence on the ability to drive and use machines. However patients should be alerted to the risk of hypoglycaemia especially when combined with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The information provided is based on a total of 9,405 patients with type 2 diabetes mellitus, including 3,750 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, who participated in one phase 2 or 12 phase 3 double-blind, placebo- or active- controlled clinical studies. In addition, a cardiovascular outcomes study with 5,380 patients with type 2 diabetes mellitus and a recent acute coronary syndrome event was conducted with 2,701 randomised to alogliptin and 2,679 randomised to placebo. These studies evaluated the effects of alogliptin on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).</p><p>In a pooled analysis of the data from 13 studies, the overall incidences of adverse events,serious adverse events and adverse events resulting in discontinuation of therapy were comparable in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo. The most common adverse reaction in patients treated with 25 mg alogliptin was headache.</p><p>The safety of alogliptin between the elderly (&ge; 65 years old) and non-elderly (&lt; 65 years old) was similar.</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions are listed by system organ class and frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from available data).</p><p>In the pooled pivotal phase 3 controlled clinical studies of alogliptin as monotherapy and as add- on combination therapy involving 5,659 patients, the observed adverse reactions are listed below (Table 1).</p><p>Table 1: Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System organ class</strong></p><p>Adverse reaction</p></td><td><p><strong>Frequency of adverse reactions</strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>upper respiratory tract infections</p></td><td><p>common</p></td></tr><tr><td><p>nasopharyngitis</p></td><td><p>common</p></td></tr><tr><td><p><strong>Immune system disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>hypersensitivity</p></td><td><p>not known</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>hypoglycaemia</p></td><td><p>common</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>headache</p></td><td><p>common</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>abdominal pain</p></td><td><p>common</p></td></tr><tr><td><p>gastroesophageal reflux disease</p></td><td><p>common</p></td></tr><tr><td><p>diarrhoea</p></td><td><p>common</p></td></tr><tr><td><p>acute pancreatitis</p></td><td><p>not known</p></td></tr><tr><td><p><strong>Hepatobiliary disorders</strong></p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:414px"><tbody><tr><td style="width:217px"><p>hepatic dysfunction including hepatic failure</p></td><td style="width:194px"><p>not known</p></td></tr><tr><td style="width:217px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="width:194px"><p>&nbsp;</p></td></tr><tr><td style="width:217px"><p>pruritus</p></td><td style="width:194px"><p>common</p></td></tr><tr><td style="width:217px"><p>rash</p></td><td style="width:194px"><p>common</p></td></tr><tr><td style="width:217px"><p>exfoliative skin conditions including Stevens-Johnson syndrome</p></td><td style="width:194px"><p>&nbsp;</p><p>not known</p></td></tr><tr><td style="width:217px"><p>erythema multiforme</p></td><td style="width:194px"><p>not known</p></td></tr><tr><td style="width:217px"><p>angioedema</p></td><td style="width:194px"><p>not known</p></td></tr><tr><td style="width:217px"><p>urticaria</p></td><td style="width:194px"><p>not known</p></td></tr></tbody></table><p><u>Post-marketing experience</u></p><p>The following adverse reactions have been identified during the post-marketing use of alogliptin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Acute pancreatitis, hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia, bullous pemphigoid, rhabdomyolysis, and diarrhea, constipation, nausea, and ileus.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999</p><p>e-mail: <u>npc.drug@sfda.gov.sa</u></p><p>Website: <u>https://ade.sfda.gov.sa</u></p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest doses of alogliptin administered in clinical studies were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of 25 mg alogliptin, respectively).</p><p><u>Management</u></p><p>In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient&#39;s clinical status.</p><p>Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little clinical benefit in overdose. It is not known if alogliptin is removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes; dipeptidyl peptidase 4 (DPP-4) inhibitors.</p><p>ATC code: A10BH04.</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt;10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. GLP-1 and GIP increases insulin biosynthesis and secretion from pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.</p><p><u>Clinical efficacy</u></p><p>Alogliptin has been studied as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).</p><p>Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing. When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.</p><p>Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p&lt;0.05). In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p&lt;0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.</p><p>A total of 14,779 patients with type 2 diabetes mellitus, including 6,448 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, participated in one phase 2 or 13 phase 3 (including the cardiovascular outcomes study) double-blind, placebo- or active- controlled clinical studies conducted to evaluate the effects of alogliptin on glycaemic control and its safety. In these studies, 2,257 alogliptin-treated patients were &ge; 65 years old and 386 alogliptin-treated patients were &ge; 75 years old. The studies included 5,744 patients with mild renal impairment, 1,290 patients with moderate renal impairment and 82 patients with severe renal impairment / end-stage renal disease treated with alogliptin.</p><p>Overall, treatment with the recommended daily dose of 25 mg alogliptin improved glycaemic control when given as monotherapy and as initial or add-on combination therapy. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g. White and non-White) were small. Clinically meaningful reductions in HbA1c compared to control were also observed with 25 mg alogliptin regardless of baseline background treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of alogliptin on body weight and lipids were neutral.</p><p><em><u>Alogliptin as monotherapy</u></em></p><p>Treatment with 25 mg alogliptin once daily resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose compared to placebo-control at Week 26 (Table 3).</p><p><em><u>Alogliptin as add-on therapy to metformin</u></em></p><p>The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (18.3%) at Week 26 (p&lt;0.001).</p><p>The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,835 mg) resulted in improvements from baseline in HbA1c at Week 52 and Week 104. At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 4) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%). At Week 104, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.72%, Table 4) was greater than that produced by glipizide plus metformin (- 0.59%). Mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin and metformin was significantly greater than that for glipizide and metformin (p&lt;0.001). By Week 104, mean change from baseline in fasting plasma glucose for 25 mg alogliptin and metformin was -3.2 mg/dL compared with 5.4 mg/dL for glipizide and metformin. More patients receiving 25 mg alogliptin and metformin (48.5%) achieved target HbA1c levels of &le; 7.0% compared to those receiving glipizide and metformin (42.8%) (p=0.004).</p><p><em><u>Alogliptin as add-on therapy to a sulphonylurea</u></em></p><p>The addition of 25 mg alogliptin once daily to glyburide therapy (mean dose = 12.2 mg) resulted in statistically significant improvements from baseline in HbA1c at Week 26 when compared to the addition of placebo (Table 3). Mean change from baseline in fasting plasma glucose at Week 26 for 25 mg alogliptin showed a reduction of 8.4 mg/dL compared to an increase of 2.2 mg/dL with placebo. Significantly more patients receiving 25 mg alogliptin (34.8%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (18.2%) at Week 26 (p=0.002).</p><p><em><u>Alogliptin as add-on therapy to a thiazolidinedione</u></em></p><p>The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).</p><p><em><u>Alogliptin as add-on therapy to a thiazolidinedione with metformin</u></em></p><p>The addition of 25 mg alogliptin once daily to 30 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 4). The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p&lt;0.001 at all time points). In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p&lt;0.001). Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%)&nbsp; achieved target HbA1c levels of &le; 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p&lt;0.001).</p><p><em><u>Alogliptin as add-on therapy to insulin (with or without metformin)</u></em></p><p>The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin therapy. More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (0.8%) at Week 26.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td colspan="4"><strong>Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF)</strong></td></tr><tr><td><strong>Study</strong></td><td><strong>Mean baseline HbA1c (%) (SD)</strong></td><td><strong>Mean change from baseline in HbA1c (%)<sup>&dagger;</sup>(SE)</strong></td><td><strong>Placebo-corrected change from baseline in HbA1c (%)<sup>&dagger;</sup> (2-sided 95% CI)</strong></td></tr><tr><td colspan="4"><em>Monotherapy placebo-controlled study</em></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily</p><p>(n=128)</p></td><td><p>7.91</p><p>(0.788)</p></td><td><p>-0.59</p><p>(0.066)</p></td><td><p>-0.57*</p><p>(-0.80, -0.35)</p></td></tr><tr><td colspan="4"><em>Add-on combination therapy placebo-controlled studies</em></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily with metformin</p><p>(n=203)</p></td><td><p>7.93</p><p>(0.799)</p></td><td><p>-0.59</p><p>(0.054)</p></td><td><p>-0.48*</p><p>(-0.67, -0.30)</p></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily&nbsp; with&nbsp; a</p><p>sulphonylurea</p><p>(n=197)</p></td><td><p>8.09</p><p>(0.898)</p></td><td><p>-0.52</p><p>(0.058)</p></td><td><p>-0.53*</p><p>(-0.73, -0.33)</p></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily with a</p><p>thiazolidinedione&nbsp; &plusmn;</p><p>metformin&nbsp; or&nbsp; a</p><p>sulphonylurea</p><p>(n=195)</p></td><td><p>8.01</p><p>(0.837)</p></td><td><p>-0.80</p><p>(0.056)</p></td><td><p>-0.61*</p><p>(-0.80, -0.41)</p></td></tr><tr><td><p>Alogliptin 25 mg once daily&nbsp;&nbsp;with</p><p>insulin <u>+</u> metformin</p><p>(n=126)</p></td><td><p>9.27</p><p>(1.127)</p></td><td><p>-0.71</p><p>(0.078)</p></td><td><p>-0.59*</p><p>(-0.80, -0.37)</p></td></tr><tr><td colspan="4"><p>FAS = full analysis set</p><p>LOCF = last observation carried forward</p><p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</p><p>* p&lt;0.001 compared to placebo or placebo+combination treatment</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td colspan="4"><strong>Table 4: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF)</strong></td></tr><tr><td><strong>Study</strong></td><td><strong>Mean baseline HbA1c (%) (SD)</strong></td><td><strong>Mean change from baseline in HbA1c (%)<sup>&dagger;</sup>(SE)</strong></td><td><strong>Treatment-corrected change from baseline in HbA1c (%)<sup>&dagger;</sup> (1-sided CI)</strong></td></tr><tr><td colspan="4"><em>Add-on combination therapy studies</em></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily with metformin vs</p><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulphonylurea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +</p><p>metformin</p><p>Change&nbsp; &nbsp;at&nbsp; &nbsp;Week&nbsp; &nbsp;52</p><p>(n=382)</p><p>Change at Week 104</p><p>(n=382)</p></td><td><p>7.61</p><p>(0.526)</p><p>7.61</p><p>(0.526)</p></td><td><p>-0.76</p><p>(0.027)</p><p>-0.72</p><p>(0.037)</p></td><td><p>-0.03</p><p>(-infinity, 0.059)</p><p>-0.13*</p><p>(-infinity, -0.006)</p></td></tr><tr><td><p>Alogliptin 25 mg once</p><p>daily with a</p><p>thiazolidinedione&nbsp; +</p><p>metformin vs a titrating</p><p>thiazolidinedione&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +</p><p>metformin</p><p>Change at Week 26</p><p>(n=303)</p><p>Change at Week 52</p><p>(n=303)</p></td><td><p>8.25</p><p>(0.820)</p><p>8.25</p><p>(0.820)</p></td><td><p>-0.89</p><p>(0.042)</p><p>-0.70</p><p>(0.048)</p></td><td><p>-0.47*</p><p>(-infinity, -0.35)</p><p>-0.42*</p><p>(-infinity, -0.28)</p></td></tr><tr><td colspan="4"><p>PPS = per protocol set</p><p>LOCF = last observation carried forward</p><p>* Non inferiority and superiority statistically demonstrated</p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</td></tr></tbody></table><p><em><u>Patients with renal impairment</u></em></p><p>The efficacy and safety of the recommended doses of alogliptin were investigated separately in a subgroup of patients with type 2 diabetes mellitus and severe renal impairment/end-stage renal disease in a placebo-controlled study (59 patients on alogliptin and 56 patients on placebo for 6 months) and found to be consistent with the profile obtained in patients with normal renal function</p><p><em><u>Elderly (&ge; 65 years old)</u></em></p><p>The efficacy of alogliptin in patients with type 2 diabetes mellitus and &ge; 65 years old across a pooled analysis of five 26-week placebo-controlled studies was consistent with that in patients &lt; 65 years old.</p><p>In addition, treatment with 25 mg alogliptin once daily resulted in improvements from baseline in HbA1c at Week 52 that were similar to those produced by glipizide (mean dose = 5.4 mg). Importantly, despite alogliptin and glipizide having similar HbA1c and fasting plasma glucose changes from baseline, episodes of hypoglycaemia were notably less frequent in patients receiving 25 mg alogliptin (5.4%) compared to those receiving glipizide (26.0%).</p><p><u>Clinical safety</u></p><p><em><u>Cardiovascular Safety</u></em></p><p>In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo.</p><p>In addition, a prospective randomised cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.</p><p>The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16]. In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>Table 5. MACE Reported in cardiovascular outcomes study</strong></p></td></tr><tr><td rowspan="3"><p>&nbsp;</p></td><td colspan="2"><p><strong>Number of Patients (%)</strong></p></td></tr><tr><td><p><strong>Alogliptin 25 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>N=2,701</p></td><td><p>N=2,679</p></td></tr><tr><td><p><strong>Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]</strong></p></td><td><p><strong>305 (11.3)</strong></p></td><td><p><strong>316 (11.8)</strong></p></td></tr><tr><td>Cardiovascular Death*</td><td>89 (3.3)</td><td>111 (4.1)</td></tr><tr><td>Nonfatal Myocardial Infarction</td><td>187 (6.9)</td><td>173 (6.5)</td></tr><tr><td>Nonfatal Stroke</td><td>29 (1.1)</td><td>32 (1.2)</td></tr><tr></tr></tbody></table><p>*Overall there were 153 subjects (5.7%) in the alogliptin group and 173 subjects (6.5%) in the placebo group who died (all-cause mortality).</p><p>There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0- 1.14].</p><p><em><u>Hypoglycaemia</u></em></p><p>In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with 12.5 mg alogliptin, active control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin, and lower than the incidence in patients treated with active control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively). In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.</p><p>In a clinical study of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another study as add-on to a sulphonylurea.</p><p>Higher rates of hypoglycaemia were observed with triple therapy with thiazolidinedione and metformin and in combination with insulin, as observed with other DPP-4 inhibitors.</p><p>Patients (&ge; 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients &ge; 65 years old treated with 25 mg alogliptin (3.8%) to that in patients &lt; 65 years old (3.6%).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Vipidia in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus.</p><p><u>Absorption</u></p><p>The absolute bioavailability of alogliptin is approximately 100%.</p><p>Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Vipidia may, therefore, be administered with or without food.</p><p>After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median T<sub>max</sub>) after dosing.</p><p>No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.</p><p>Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to 100 mg alogliptin (covering the therapeutic dose range). The inter-subject coefficient of variation for alogliptin AUC was small (17%).</p><p><u>Distribution</u></p><p>Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the active substance is well distributed into tissues.</p><p>Alogliptin is 20-30% bound to plasma proteins.</p><p><u>Biotransformation</u></p><p>Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.</p><p>Two minor metabolites were detected following administration of an oral dose of [<sup>14</sup>C] alogliptin, N-demethylated alogliptin, M-I (&lt; 1% of the parent compound), and N-acetylated alogliptin, M-II (&lt; 6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. <em>In vitro </em>data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p><p><em>In vitro </em>studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. Studies <em>in vitro </em>have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies <em>in vivo</em>.</p><p>In studies <em>in vitro</em>, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2.</p><p>Alogliptin exists predominantly as the (R)-enantiomer (&gt; 99%) and undergoes little or no chiral conversion <em>in vivo </em>to the (S)-enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.</p><p><u>Elimination</u></p><p>Alogliptin was eliminated with a mean terminal half-life (<sub>T1/2</sub>) of approximately 21 hours.</p><p>Following administration of an oral dose of [<sup>14</sup>C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.</p><p>The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.</p><p><u>Time-dependency</u></p><p>Total exposure (AUC<sub>(0-inf)</sub>) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC<sub>(0-24)</sub>) after 6 days of once daily dosing. This indicates no time-dependency in the kinetics of alogliptin after multiple dosing.</p><p><u>Special populations</u></p><p><em><u>Renal impairment</u></em></p><p>A single-dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = &gt; 50 to &le; 80 mL/min), moderate (CrCl = &ge; 30 to &le; 50 mL/min), severe (CrCl = &lt; 30 mL/min) and end-stage renal disease on haemodialysis.</p><p>An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment for patients with mild renal impairment is necessary (see section 4.2).</p><p>In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the active substance was removed during a 3-hour haemodialysis session.) Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see section 4.2).</p><p><em><u>Hepatic impairment</u></em></p><p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to healthy control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9, see section 4.2).</p><p><em><u>Age, gender, race, body weight</u></em></p><p>Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see section 4.2).</p><p><em><u>Paediatric population</u></em></p><p>The pharmacokinetics of alogliptin in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology.</p><p>The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26 and 39 weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended dose of 25 mg alogliptin.</p><p>Alogliptin was not genotoxic in a standard battery of <em>in vitro </em>and <em>in vivo </em>genotoxicity studies.</p><p>Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. Minimal to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect level).</p><p>No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. Although fertility&nbsp; was&nbsp; not affected, a slight,&nbsp; statistical&nbsp; increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose.</p><p>Placental transfer of alogliptin occurs in rats.</p><p>Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights.</p><p>In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight.</p><p>Studies in lactating rats indicate that alogliptin is excreted in milk.</p><p>No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><ul><li>Mannitol</li><li>Microcrystalline cellulose</li><li>Hydroxypropyl cellulose</li><li>Croscarmellose sodium</li><li>Magnesium stearate</li></ul><p><u>Tablet coat:</u></p><ul><li>Hypromellose</li><li>Titanium dioxide</li><li>Ferric oxide red</li><li>Polyethylene glycol</li></ul><p><u>Printing ink:</u></p><ul><li>Opacode black.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p><p>Pack size: 28 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries 
Al-Kharj Road
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: jpimedical@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 October 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>